|
業務類別
|
Biotechnology |
|
業務概覽
|
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K. |
| 公司地址
| 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021 |
| 電話號碼
| +1 604 210-2217 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.achievelifesciences.com |
| 員工數量
| 28 |
| Mr. Mark K. Oki |
Chief Financial Officer |
-- |
08/06/2026 |
| Mr. Jerry Wan |
Principal Accounting Officer and Vice President, Finance |
-- |
24/03/2026 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
-- |
16/04/2026 |
| Mr. Erik Atkisson |
Chief Legal Officer |
美元 130.26K |
08/06/2026 |
| Mr. Craig Donnelly |
Chief Operations Officer |
-- |
08/06/2026 |
| Mr. Mark Lawrence Rubinstein |
Chief Medical Officer |
-- |
08/06/2026 |
|
|
| Mr. Jeffrey S. Farrow |
Independent Director |
08/06/2026 |
| Mr. Richard Alistair Balfour Stewart |
Director |
16/04/2026 |
| Dr. Aaron Royston, M.D. |
Independent Director |
12/05/2026 |
| Dr. Andrew Goldberg, M.D. |
Chief Executive Officer, President and Director |
16/04/2026 |
| Dr. Lucian Iancovici, M.D. |
Chairman of the Board |
12/05/2026 |
| Mr. Thomas Sellig |
Independent Director |
08/06/2026 |
| Ms. Nancy R. Phelan |
Independent Director |
08/06/2026 |
| Mr. Christopher Martin |
Director |
12/05/2026 |
| Mr. Jeffery Farrow |
Director |
02/06/2026 |
| Dr. Reid Waldman, M.D. |
Director |
02/06/2026 |
| Mr. Chris Martin |
Independent Director |
08/06/2026 |
|
|
|
|
